# A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct04495296/  
OnCo record `nct04495296` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CAPOX, Capecitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., now recruiting.

## Summary

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04495296 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 320 participants planned, started 2020-08-13 and due to reach its primary completion in 2026-06-25. Interventions recorded: TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine. Conditions listed: Advanced Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04495296
- Phase: 1/2
- Setting: A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid Tumors
- Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT04495296: https://clinicaltrials.gov/study/NCT04495296

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [TST001](https://onco.cc/drugs/tst001/)

---
JSON: https://onco.cc/api/v1/entities/nct04495296.json